Randall K. Holmes

TL;DR: Although Shigella dysenteriae serotype 1 (Shiga) toxin was discovered more than 80 years ago and has long been recognized as one of the most potent bacterial toxins, early efforts to characterize its structure, biologic activity, genetics, role in pathogenesis, and other properties were hindered by difficulties in preparing pure toxin, obtaining appropriate immunologic reagents, and conducting genetic studies.

TL;DR: One of these phages and another Shiga-like toxin-converting phage from an Escherichia coli O26 isolate associated with infantile diarrhea were closely related in terms of morphology, virion polypeptides, DNA restriction fragments, lysogenic immunity, and heat stability, although a difference in host range was noted.

TL;DR: Findings indicate that E. coli produces two genetically related but antigenically distinct cytotoxins with similar biologic activities which are proposed to name Shiga-like toxins I and II.

TL;DR: The nucleotide sequence of the Shiga-like toxin type II (SLT-II) structural genes cloned from bacteriophage 933W of the enterohemorrhagic Escherichia coli O157:H7 strain 933 was determined and the regulation proposed for the SLT -II operon is similar to that previously proposed for SLT-I.

TL;DR: The hypothesis that SLT-IIv binds to a different cellular receptor than do other members of the Shiga toxin family but has a similar mode of intracellular action is supported.